Astrazeneca (AZN) Notes Payables (2016 - 2025)
Historic Notes Payables for Astrazeneca (AZN) over the last 16 years, with Q4 2025 value amounting to -$13.0 million.
- Astrazeneca's Notes Payables rose 7796.61% to -$13.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$13.0 million, marking a year-over-year increase of 7796.61%. This contributed to the annual value of -$13.0 million for FY2025, which is 7796.61% up from last year.
- Latest data reveals that Astrazeneca reported Notes Payables of -$13.0 million as of Q4 2025, which was up 7796.61% from -$63.0 million recorded in Q3 2025.
- Astrazeneca's 5-year Notes Payables high stood at -$13.0 million for Q4 2025, and its period low was -$980.0 million during Q1 2024.
- Its 5-year average for Notes Payables is -$308.0 million, with a median of -$252.0 million in 2023.
- As far as peak fluctuations go, Astrazeneca's Notes Payables tumbled by 122432.43% in 2024, and later surged by 8912.13% in 2025.
- Quarter analysis of 5 years shows Astrazeneca's Notes Payables stood at -$291.0 million in 2021, then soared by 37.11% to -$183.0 million in 2022, then fell by 10.93% to -$203.0 million in 2023, then soared by 70.94% to -$59.0 million in 2024, then skyrocketed by 77.97% to -$13.0 million in 2025.
- Its Notes Payables stands at -$13.0 million for Q4 2025, versus -$63.0 million for Q3 2025 and -$26.0 million for Q2 2025.